Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07219953 · ClinicalTrials.gov registry record · Phase 3
A Study of Brenipatide in Participants With Alcohol Use Disorder
A Phase 3 study of Alcohol Use Disorder, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,100
- Enrollment target
- 20
- Study locations
NCT07219953 is a Phase 3 study of Alcohol Use Disorder that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 1,100 participants, above the 322-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (242% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT07219953, a Phase 3 study of Alcohol Use Disorder, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with Alcohol Use Disorder (AUD) and hazardous alcohol use. Participation in this study will last approximately 56 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY3537031
Study Locations (20)
Florida
- Accel Research Sites - Lakeland Clinical Research Unit - Lakeland
- Innovative Clinical Research - Lauderhill
- K2 Medical Research - Maitland - Maitland
- K2 Medical Research ORLANDO - Maitland
- Life Arc Research Centers - Miami - Miami
- Wellness Research Center - Miami
- Life Medical Research Group Corp - Miami Gardens
- Charter Research - Orlando - Orlando
- K2 Medical Research - Tampa - Tampa
California
- UCLA Clinical & Translational Research Center (CTRC) - Los Angeles
- Artemis Institute for Clinical Research - Riverside
- Artemis Institute for Clinical Research - San Diego
- UCSF Weill Institute for Neurosciences - Substance Use Disorders Clinic - Mission Bay - San Francisco
Maryland
- Maryland Treatment Centers - Mountain Manor Treatment Center - Baltimore
- Maryland Treatment Centers - Avery Road Treatment Center - Rockville
Alabama
- Parkway Medical Center - Birmingham
Arizona
- Headlands Research - Scottsdale - Scottsdale
Arkansas
- Woodland International Research Group - Little Rock
Illinois
- Re:Cognition Health - Chicago - Chicago
Massachusetts
- Adams Clinical Boston - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2025-10-16 |
| Est. Completion | 2028-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07219953
The ClinicalTrials.gov registry entry for NCT07219953 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 322-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (242% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07219953 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT07219953 about?
NCT07219953 is a clinical study titled "A Study of Brenipatide in Participants With Alcohol Use Disorder". The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with Alcohol Use Disorder (AUD) and hazardous alcohol use. Participation in this study will last approximately 56 weeks.
What is the current status of trial NCT07219953?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,100 participants. The study started on 2025-10-16. Estimated completion is 2028-04.
What conditions does trial NCT07219953 study?
This clinical trial studies the following conditions: Alcohol Use Disorder.
What interventions are being tested in trial NCT07219953?
The interventions under investigation include: Placebo (DRUG), LY3537031 (DRUG).
Who is sponsoring clinical trial NCT07219953?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07219953 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Emergency Department-Initiated Medications for Alcohol Use Disorder
RECRUITING · Phase 3
-
Electronic Harm Reduction Treatment for Alcohol
RECRUITING · Phase 3
-
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
RECRUITING · Phase 3
-
Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action
COMPLETED · Phase 3
-
Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking
RECRUITING · Phase 2
-
Ultrasound Neuromodulation of the Brain for Alcohol Use Disorder
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.